According to the Financial Intelligence APP, Hemco Medical Technology (02576) has announced that the stabilisation period for the global offering has ended on November 2, 2024 (Saturday) (i.e. 30 days after the deadline for submitting applications for public offering in Hong Kong).

The stabilising manager Morgan Stanley Asia Limited and its affiliates or any person acting in concert acquired a total of 3.8668 million H shares during the stabilisation period, accounting for approximately 15.00% of the total number of shares available for subscription and sale in the global offering (after exercising the over-allotment option but before any exercise of the over-allotment option).

During the stabilisation period, purchases of a total of 3.8668 million H shares were made at a price ranging from HK$5.79 to HK$11.66 per H share to facilitate the delivery of these H shares to the underwriters who have agreed to delay the receipt of the 3.8668 million H shares subscribed under the global offering. During the stabilisation period, the stabilising manager, its affiliates or any person acting in concert made the final purchases at a price of HK$6.06 per H share on November 1, 2024 (Friday).

The overall coordinator (on its own behalf and on behalf of the international underwriters) did not exercise the over-allotment option during the stabilisation period, and the over-allotment option expired on November 2, 2024 (Saturday). Therefore, there is no issuance or planned issuance of H shares under the over-allotment option.